Trevena (NASDAQ:TRVN – Get Free Report) is expected to issue its resultson Thursday, November 5th. Analysts expect Trevena to announce earnings of ($50.00) per share and revenue of $0.78 million for the quarter.
Trevena Stock Performance
NASDAQ TRVN opened at $0.01 on Wednesday. The stock has a market cap of $10,644.90, a PE ratio of -0.00 and a beta of -0.55. Trevena has a twelve month low of $0.00 and a twelve month high of $1.50. The stock has a fifty day simple moving average of $0.01 and a 200-day simple moving average of $0.01.
About Trevena
Trevena, Inc is a biopharmaceutical company focused on developing medicines for the treatment of acute and chronic pain, as well as disorders of the central nervous system. The company’s research has centered on G protein–coupled receptors and its “biased ligand” drug-discovery platform, which is intended to produce therapeutic effects while potentially reducing certain side effects associated with conventional treatments.
Trevena’s principal commercial product is OLINVYK (oliceridine) injection, an opioid analgesic approved by the U.S.
Read More
- Five stocks we like better than Trevena
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
